A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts

[1]  Adele Lafrance,et al.  The Road Map , 2020, What to Say to Kids When Nothing Seems to Work.

[2]  L. Álvarez-Vallina,et al.  Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice. , 2019, Molecular pharmaceutics.

[3]  J. Zapata,et al.  A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity , 2018, Nature Communications.

[4]  Sultan Gulce-Iz,et al.  Monoclonal antibodies in cancer immunotherapy , 2018, Molecular Biology Reports.

[5]  L. Aghebati-Maleki,et al.  Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy , 2018, Journal of cellular physiology.

[6]  W. Wilson,et al.  Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia , 2018, Leukemia.

[7]  Liankun Sun,et al.  Targeted delivery of immuno-RNase may improve cancer therapy , 2018, Cancer Cell International.

[8]  I. Pastan,et al.  Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin , 2018, The Journal of Immunology.

[9]  L. Álvarez-Vallina,et al.  ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy , 2017, Oncoimmunology.

[10]  S. Halford,et al.  The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity , 2017, Cancer Immunology, Immunotherapy.

[11]  P. Mokarram,et al.  Novel biotechnology approaches in colorectal cancer diagnosis and therapy , 2017, Biotechnology Letters.

[12]  J. Wolchok,et al.  Combination immunotherapy: a road map , 2017, Journal of Immunotherapy for Cancer.

[13]  J. Gavilanes,et al.  Fungal Ribotoxins: A Review of Potential Biotechnological Applications , 2017, Toxins.

[14]  C. Klein,et al.  Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines , 2017, Oncoimmunology.

[15]  L. Álvarez-Vallina,et al.  Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity , 2017, Gene Therapy.

[16]  R. Holgate,et al.  A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead , 2016, Protein engineering, design & selection : PEDS.

[17]  B. Oliva,et al.  Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains , 2016, Scientific Reports.

[18]  Norma E. Conner,et al.  Advances and Challenges , 2016, The American journal of hospice & palliative care.

[19]  J. Gavilanes,et al.  Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A , 2015, The FEBS journal.

[20]  R. Fischer,et al.  Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities , 2015, Journal of Cancer Research and Clinical Oncology.

[21]  J. Gavilanes,et al.  Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts , 2015, SpringerPlus.

[22]  I. Pastan,et al.  Advances in anticancer immunotoxin therapy. , 2015, The oncologist.

[23]  J. Gavilanes,et al.  α‐sarcin and RNase T1 based immunoconjugates: the role of intracellular trafficking in cytotoxic efficiency , 2015, The FEBS journal.

[24]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[25]  L. Álvarez-Vallina,et al.  Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris , 2014, Microbial Cell Factories.

[26]  L. Álvarez-Vallina,et al.  Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications , 2014, Oncoimmunology.

[27]  S. Dübel,et al.  Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform , 2014, mAbs.

[28]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[29]  P. Sapra,et al.  Monoclonal antibody-based therapies in cancer: advances and challenges. , 2013, Pharmacology & therapeutics.

[30]  B. Oliva,et al.  Generation and characterization of monospecific and bispecific hexavalent trimerbodies , 2013, mAbs.

[31]  C. Batt,et al.  Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells , 2012, The FEBS journal.

[32]  C. Batt,et al.  Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin. , 2012, Protein engineering, design & selection : PEDS.

[33]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[34]  R. Verma,et al.  Therapeutic potential of anticancer immunotoxins. , 2011, Drug discovery today.

[35]  Baldomero Oliva,et al.  Multivalent antibodies: when design surpasses evolution. , 2010, Trends in biotechnology.

[36]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[37]  D. Holzman.  Whatever happened to immunotoxins? Research, and hope, are still alive. , 2009, Journal of the National Cancer Institute.

[38]  B. Oliva,et al.  In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences , 2009, PloS one.

[39]  Michael Dougan,et al.  Immune therapy for cancer. , 2009, Annual review of immunology.

[40]  J. Gavilanes,et al.  The therapeutic potential of fungal ribotoxins. , 2008, Current pharmaceutical biotechnology.

[41]  Michael M. Schmidt,et al.  Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability , 2008, Cancer Immunology, Immunotherapy.

[42]  J. Gavilanes,et al.  Fungal ribotoxins: molecular dissection of a family of natural killers. , 2007, FEMS microbiology reviews.

[43]  I. Pastan,et al.  Immunotoxin treatment of cancer. , 2007, Annual review of medicine.

[44]  K. Chester,et al.  A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug , 2006, Clinical Cancer Research.

[45]  J. Prieto,et al.  Enhanced antiangiogenic therapy with antibody‐collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events , 2006, International journal of cancer.

[46]  C. Verschraegen,et al.  Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. , 2004, Anticancer research.

[47]  L. Álvarez-Vallina,et al.  Antibodies and gene therapy: teaching old 'magic bullets' new tricks. , 2004, Trends in immunology.

[48]  R. Kreitman.  Recombinant toxins for the treatment of cancer. , 2003, Current opinion in molecular therapeutics.

[49]  J. Turnay,et al.  Cytotoxic mechanism of the ribotoxin α‐sarcin , 2001 .

[50]  R. Kreitman.  Immunotoxins , 2000, Expert opinion on pharmacotherapy.

[51]  A. Goyal,et al.  Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. , 2000, The Biochemical journal.

[52]  S. Hammarström.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. , 1999, Seminars in cancer biology.

[53]  V. Diehl,et al.  Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. , 1998, Leukemia & lymphoma.

[54]  M. Ratain,et al.  Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. , 1998, Blood.

[55]  J. Batra,et al.  Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action. , 1997, The Biochemical journal.

[56]  R. Hawkins,et al.  Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.

[57]  M. Neumaier,et al.  CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[58]  J. Turnay,et al.  Kinetic study of the cytotoxic effect of α-sarcin, a ribosome inactivating protein fromAspergillus giganteus, on tumour cell lines: protein biosynthesis inhibition and cell binding , 1993, Molecular and Cellular Biochemistry.

[59]  A. Cumber,et al.  Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus. , 1991, European journal of biochemistry.

[60]  Phil Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[61]  H. Pommergaard,et al.  The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. , 2016, International journal of surgery.

[62]  R. Kreitman.  Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies , 2012, BioDrugs.

[63]  J. Turnay,et al.  Cytotoxic mechanism of the ribotoxin alpha-sarcin. Induction of cell death via apoptosis. , 2001, European journal of biochemistry.

[64]  U. Brinkmann.  Recombinant antibody fragments and immunotoxin fusions for cancer therapy. , 2000, In vivo.

[65]  F. Foss,et al.  Diphtheria toxin fusion proteins. , 1998, Current topics in microbiology and immunology.

[66]  D. Esseltine,et al.  Clinical trials with blocked ricin immunotoxins. , 1998, Current topics in microbiology and immunology.

[67]  S. Nayak,et al.  Overproduction of fungal ribotoxin alpha-sarcin in Escherichia coli: generation of an active immunotoxin. , 1997, Gene.

[68]  Immunotoxins. , 1988, Cancer treatment and research.

[69]  M. Gasset,et al.  Conformational study of the antitumor protein α-sarcin , 1988 .